Guangdong Kanghua Healthcare Group Valuation

Q: What is the Fair Price of E9Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

E9Q (€0.2) is trading below our estimate of [[fair value]] (€0.25)

Is E9Q undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of E9Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: E9Q (€0.2) is trading below our estimate of fair value (€0.25)

Significantly Below Fair Value: E9Q is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for E9Q?

Key metric: As E9Q is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for E9Q. This is calculated by dividing E9Q's market cap by their current earnings.
What is E9Q's PE Ratio?
PE Ratio	11.4x
Earnings	CN¥50.87m
Market Cap	CN¥578.00m

E9Q key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.2x
Enterprise Value/EBITDA	2.3x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does E9Q's PE Ratio compare to its peers?

The above table shows the PE ratio for E9Q vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	16.5x
LIK LIMES Schlosskliniken	22.5x	n/a	€96.2m
M12 M1 Kliniken	18.2x	17.5%	€305.2m
JTH Gesundheitswelt Chiemgau	6.8x	n/a	€23.8m
RHK RHÖN-KLINIKUM	18.4x	7.5%	€823.3m
E9Q Guangdong Kanghua Healthcare Group	11.4x	n/a	€622.0m

Price-To-Earnings vs Peers: E9Q is good value based on its Price-To-Earnings Ratio (11.4x) compared to the peer average (16.5x).

Price to Earnings Ratio vs Industry

How does E9Q's PE Ratio compare vs other companies in the European Healthcare Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: E9Q is good value based on its Price-To-Earnings Ratio (11.4x) compared to the European Healthcare industry average (18.8x).

Price to Earnings Ratio vs Fair Ratio

What is E9Q's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

E9Q PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	11.4x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate E9Q's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sensus Healthcare

US$143.9m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

5TX

US$8.25

4.4%

263.8%

Shandong Weigao Group Medical Polymer

HK$20.2b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

-1.9%

-37.7%

LNA Santé

€240.3m

Engages in the management and operation of health establishments.

2N3

€23.00

1.5%

17.7%